Ironwood Pharmaceuticals (IRWD) Current Deferred Revenue (2010 - 2026)

Ironwood Pharmaceuticals (IRWD) has 15 years of Current Deferred Revenue data on file, last reported at $1.5 million in Q1 2026.

• For the quarter ending Q1 2026, Current Deferred Revenue fell 18.04% year-over-year to $1.5 million; the trailing twelve-month figure through Mar 2026 stood at $1.5 million (down 18.04% YoY), and the FY2025 full-year result was $1.1 million, down 45.52% from the prior year.
• Current Deferred Revenue rose to $1.5 million in Q1 2026, from $1.1 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $2.6 million in Q4 2023 to a low of $978000.0 in Q2 2025.
• A 4-year average of $1.6 million and a median of $1.5 million in 2026 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue plunged 45.52% in 2025 and slipped 18.04% in 2026, its largest moves.
• Tracing IRWD's Current Deferred Revenue over 4 years: stood at $2.6 million in 2023, then dropped by 22.44% to $2.0 million in 2024, then tumbled by 45.52% to $1.1 million in 2025, then soared by 32.97% to $1.5 million in 2026.
• Business Quant data shows IRWD's Current Deferred Revenue at $1.5 million in Q1 2026, $1.1 million in Q4 2025, and $1.0 million in Q3 2025.